Reprint

Key Advances in the Treatment of the Critically Ill

Edited by
March 2024
260 pages
  • ISBN978-3-7258-0267-8 (Hardback)
  • ISBN978-3-7258-0268-5 (PDF)

This is a Reprint of the Special Issue Key Advances in the Treatment of the Critically Ill that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

This reprint of a Special Issue of the Journal of Clinical Medicine includes a submission-motivating editorial, eleven clinical research papers (including a meta-analysis), six narrative reviews and a survey-based study, focusing on a wide variety of aspects of intensive care.  Five studies pertain to coronavirus disease-19 (COVID-19) assess intermittent vs. prolonged prone ventilation and the interaction between early pressure-supported ventilation and kidney injury, as well as the clinical significance of biomarkers (pro-adrenomedullin and heparinase) and of an impaired antibody response.  The COVID-19 narrative reviews analyze published evidence on therapeutic interventions in COVID-19-related acute respiratory distress syndrome (ARDS) and invasive fungal infections.  The remaining six studies assess the Norwegian version of the Chelsea physical assessment tool, the interaction of base excess and lactate in outcome prediction, left ventricular dysfunction in ARDS, respiratory drive after isoflurane sedation, renal preplacement therapy as a prognostic factor and diaphragmatic dysfunction in severe trauma patients.  The remaining four narrative reviews analyze published evidence on immunoglobulins in sepsis, treatments for post-cardiac arrest syndrome, blood purification in sepsis and the management of traumatic brain injury.  Lastly, the survey-based study explores the temporal evolution of European resuscitation and end-of-life practices.  The Special Issue primarily aims to publish both innovative research findings and comprehensive reviews of existing scientific knowledge on acute and life-threatening disease.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
fungal infections; critically ill; CAPA; COVID-19; CAM; CAC; acute kidney injury; chronic kidney disease; continuous renal replacement therapy; end-stage of kidney disease; intermittent hemodialysis; mortality; renal replacement therapy; n/a; COVID-19; SARS-CoV-2; critical care; antibody response; NET; histones; ethics; resuscitation; terminal care; surveys and questionnaires; emergency care; proadrenomedullin; MR-proADM; SARS-CoV-2; COVID-19; biomarkers; intensive care; endothelitis; brain trauma; intracranial hypertension; neuromonitoring; COVID-19; acute respiratory distress syndrome; mechanical ventilation; SARS-CoV-2; COVID-19; ARDS; endothelial dysfunction; heparanase; heparan sulfate; biomarker; intensive care; anesthesia; inhaled sedation; respiratory drive; isoflurane; propofol; ARDS; left ventricular diastolic dysfunction; total lung weight; base excess; alactic base excess; hyperlactatemia; mortality; shock; septic shock; sepsis mediators; hemofiltration; hemoadsorption; COVID-19; mechanical ventilation; acute kidney injury (AKI); acute respiratory distress syndrome (ARDS); ventilator-induced kidney injury (VIKI); multiple trauma; thoracic trauma; mechanical ventilation; diaphragmatic muscle; diaphragmatic dysfunction; ventilator-induced diaphragmatic dysfunction; ARDS; prone position; COVID-19; mechanical ventilation; cardiac arrest; post-resuscitation care; intensive care medicine; critical care; outcome; sepsis; septic shock; immunotherapy; physiotherapy; physical function; early rehabilitation; measurement tool; critical illness; CPAx; critical care